title: Mifepristone and misoprostol for early medical abortion: 18 months experience in the United States.
abstract: In the first 18 months since mifepristone was approved by the Food and Drug Administration (FDA) for use with misoprostol for early medical abortion, approximately 80,000 women have been treated. One-hundred thirty-nine adverse events were reported to Danco Laboratories LLC and subsequently reported to the FDA. Thirteen patients required blood transfusions, 10 patients were treated with antibiotics for infection and 6 had a generalized allergic reaction. Fifty patients had an ongoing pregnancy, with 48 having suction curettage, leaving 2 ongoing pregnancies. Thirty-nine patients had a suction curettage for heavy or prolonged vaginal bleeding. The overall national experience has been highly favorable.
authors.affiliation: Department of Obstetrics, Gynecology and Reproductive Medicine, The Mount Sinai School of Medicine and Danco Laboratories, LLC, 131 East 65th Street, New York, NY 10021, USA. Ushar@RCN.com
authors.forename: Richard
authors.initials: R
authors.lastname: Hausknecht
mesh_terms: D000020:Abortifacient Agents, Nonsteroidal / Q000009:adverse effects*; D000021:Abortifacient Agents, Steroidal / Q000009:adverse effects*; D000028:Abortion, Induced / Q000009:adverse effects* / Q000379:methods; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001803:Blood Transfusion / Q000706:statistics & numerical data; D005260:Female; D005865:Gestational Age; D006801:Humans; D006967:Hypersensitivity / Q000453:epidemiology; D007239:Infections / Q000188:drug therapy / Q000453:epidemiology; D015735:Mifepristone / Q000009:adverse effects*; D016595:Misoprostol / Q000009:adverse effects*; D011247:Pregnancy; D014481:United States / Q000453:epidemiology; D014592:Uterine Hemorrhage / Q000601:surgery; D014619:Vacuum Curettage
chemical_list: D000020:Abortifacient Agents, Nonsteroidal; D000021:Abortifacient Agents, Steroidal; D000900:Anti-Bacterial Agents; D016595:Misoprostol; D015735:Mifepristone